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ABSTRACT 1 
Background. Inhaled corticosteroids (ICS) are the most widely prescribed and effective 2 
medication to control asthma symptoms and exacerbations. However, many children still have 3 
asthma exacerbations despite treatment, particularly in admixed populations, such as Puerto 4 
Ricans and African Americans. A few genome-wide association studies (GWAS) have been 5 
performed in European and Asian populations, and they have demonstrated the importance of 6 
the genetic component in ICS response.  7 
Objective. We aimed to identify genetic variants associated with asthma exacerbations in 8 
admixed children treated with ICS, and to validate previous GWAS findings. 9 
Methods. A meta-analysis of two GWAS of asthma exacerbations was performed in 1,347 10 
admixed children treated with ICS (Hispanics/Latinos and African Americans), analyzing 8.7 11 
million genetic variants. Those with p≤5x10-6 were followed up for replication in 1,697 12 
asthmatic patients from six European studies. Associations of ICS response described in 13 
published GWAS were followed up for replication in the admixed populations. 14 
Results. A total of 15 independent variants were suggestively associated with asthma 15 
exacerbations in admixed populations (p≤5x10-6). One of them, located in the intergenic 16 
region of APOBEC3B and APOBEC3C, showed evidence of replication in Europeans 17 
(rs5995653, p = 7.52x10-3) and was also associated with change in lung function after 18 
treatment with ICS (p = 4.91x10-3). Additionally, the reported association of the L3MBTL4-19 
ARHGAP28 genomic region was confirmed in admixed populations, although a different 20 
variant was identified. 21 
Conclusions & Clinical Relevance. This study revealed the novel association of APOBEC3B 22 
and APOBEC3C with asthma exacerbations in children treated with ICS and replicated 23 
previously identified genomic regions. This contributes to the current knowledge about the 24 
multiple genetic markers determining responsiveness to ICS which could lead in the future 25 
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the clinical identification of those asthma patients who are not able to respond to such 26 
treatment. 27 
Keywords: African American, childhood asthma, exacerbations, Latino, pharmacogenomics. 28 
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INTRODUCTION 29 
Asthma is the most common chronic condition in children and young adults. In addition 30 
to the direct impact of the illness on the individual, severe exacerbations of asthma generate 31 
considerable economic costs to healthcare systems, as well as work and/or school absenteeism 32 
[1].  33 
Inhaled corticosteroids (ICS) are the most effective and commonly prescribed 34 
medications for symptom control and prevention of severe asthma exacerbations [1]. While 35 
most children using ICS experience a decrease in their asthma symptoms, 30-40% will 36 
continue to experience exacerbations, and of these non-responders, 10-15% may even have an 37 
increase in their exacerbations [2]. High variability in ICS response has been described also 38 
among ethnicities [3]. In addition to high asthma morbidity, exacerbations rates and mortality, 39 
admixed populations have reduced ICS response [4]. These strong ethnic differences suggest 40 
a substantial hereditary component in the ICS response [5]. In fact, approximately 40-60% of 41 
the variation in ICS response may be due to genetic factors [6].  42 
For several decades, pharmacogenetic studies have utilized candidate-gene approaches, 43 
which only evaluate a small portion of the genetic variation. More recently, these have 44 
evolved towards hypothesis-free approaches by implementing genome-wide association 45 
studies (GWAS) [7]. Eight GWAS of ICS response have been performed to date [8-15], 46 
revealing an association between 14 genomic regions and this trait. 47 
However, the polymorphisms identified by GWAS to date only represent a small 48 
proportion of the heritability of ICS response, and hence it is not possible to predict an 49 
individual’s response to this treatment [16]. The design of the GWAS performed to date may 50 
be the main reason, where analyses are statistically underpowered to detect genetic 51 
associations. Most GWAS of ICS response have included a relatively small number of 52 
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individuals (N<1,000) of primarily European and, to a lesser extent, Asian ancestry, with poor 53 
representation of admixed populations [4], which include Hispanics/Latinos and African 54 
Americans. However, the increased asthma prevalence among admixed individuals with 55 
African ancestry, such as Puerto Ricans and African Americans, and the greater genetic 56 
diversity and specific genetic background of these populations present a unique opportunity to 57 
study the response to ICS treatment in asthma [3-4]. 58 
We hypothesized that a large pharmacogenetic study of ICS response in admixed 59 
individuals with asthma that exhaustively explores the association of genetic variants across 60 
the genome could reveal novel genes associated with this trait. We also attempted to evaluate 61 
whether the associations described in GWAS performed in European and Asian populations 62 
could be generalized to admixed populations. 63 
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METHODS 64 
Study Populations 65 
A total of eight independent studies participating in the Pharmacogenomics in 66 
Childhood of Asthma (PiCA) consortium [17] were analyzed as part of discovery and 67 
replication phases of this meta-GWAS. Individuals from two admixed populations were 68 
included in the discovery phase: the Genes-environments & Admixture in Latino Americans 69 
Study (GALA II) and the Study of African Americans, Asthma, Genes and Environments 70 
(SAGE). Samples from six European PiCA studies were used for replication. All studies have 71 
been approved by their local institutional review boards and all participants/parents provided 72 
written informed assent and consent, respectively. GALA II and SAGE were approved by the 73 
Human Research Protection Program Institutional Review Board of the University of 74 
California, San Francisco (San Francisco, United States) (ethics approval numbers: 217802 75 
and 210362, respectively). PACMAN was approved by the Medical Ethics Committee of the 76 
University Medical Centre Utrecht (Utrecht, the Netherlands). The Tayside Committee on 77 
Medical Research Ethics (Dundee, United Kingdom) approved BREATHE. PASS was 78 
approved by the Liverpool Paediatric Research Ethics Committee (Liverpool, United 79 
Kingdom) (reference number: 08/H1002/56). SLOVENIA was approved by the Slovenian 80 
National Medical Ethics Committee (Ljubljana, Slovenia). ESTATe was approved by the 81 
Medische Ethische Toetsings Commissie, Erasmus Medical Center (Rotterdam, the 82 
Netherlands) (ethics approval number: MEC-2011-474). followMAGICS was approved by 83 
the Ethik-Kommission der Bayerischen Landesärztekammer (Munich, Germany) (ethics 84 
reference number: 01218). 85 
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Discovery phase 86 
Patients from the GALA II and SAGE studies with a physician diagnosis of asthma who 87 
reported having active symptoms and asthma medication use within the last year were 88 
analyzed in the discovery phase. These are two independent studies focused on two different 89 
racial/ethnic groups based on the self-identified ethnicity of the four grandparents of each 90 
subject: Hispanics/Latinos (GALA II) and African Americans (SAGE). Both studies recruited 91 
unrelated children and young adults, aged 8 to 21 years old, using the same protocol and 92 
questionnaires from different areas in the United States. GALA II also recruited individuals in 93 
Puerto Rico [18]. 94 
Analyses were performed for a subset of 854 subjects from GALA II and 493 95 
individuals from SAGE. Specifically, we assessed self-reported ICS use, age, gender, 96 
genome-wide genotypic data [19-20], and information regarding presence or absence of 97 
severe asthma exacerbations, as defined by the European Respiratory Society (ERS) and the 98 
American Thoracic Society (ATS) [21]. We examined exacerbations that occurred during the 99 
12 months preceding the study enrollment (need to seek emergency asthma care, 100 
hospitalizations or the administration of oral corticosteroids).  101 
Replication phase 102 
Validation was carried out in European individuals from six independent studies 103 
participating in the PiCA consortium: the follow-up stage of the Multicenter Asthma Genetics 104 
in Childhood Study (followMAGICS); the Pharmacogenetics of Adrenal Suppression study 105 
(PASS); Pharmacogenetics of Asthma Medication in Children: Medication with Anti-106 
inflammatory effects (PACMAN); Effectiveness and Safety of Treatment with Asthma 107 
Therapy in Children (ESTATe); BREATHE and SLOVENIA studies. Details for each study 108 
are described in the Supporting Information. 109 
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The use of ICS and availability of data related to the presence/absence of asthma 110 
exacerbations during the previous 12 or 6 months were also applied as inclusion criteria for 111 
the individuals from these studies analyzed in the current study, whereas non-availability of 112 
data related to ICS use, asthma exacerbations, age, gender and genotype data were considered 113 
as exclusion criteria. For those studies without data related to the events included in the 114 
ATS/ERS definition of asthma exacerbations, information regarding school absences, 115 
unscheduled general practitioner (GP) or respiratory system specialist visits was also 116 
considered. 117 
Genome-wide genotyping, genetic ancestry assessment and imputation 118 
Both GALA II and SAGE samples were genotyped using the Axiom® LAT1 array 119 
(Affymetrix Inc.), and quality control (QC) procedures were performed as described 120 
elsewhere [19-20]. Genotyping of the subjects included in the replication phase was 121 
performed on different genotyping platforms, as described in previous publications (see 122 
Supporting Information) (Table S1). In addition, four of the studies were genotyped for the 123 
purposes of the PiCA consortium and their QC is described in the Supporting Information. 124 
Genetic ancestry was assessed by means of Principal Component (PC) analysis with 125 
EIGENSOFT 6.14 for the studies included in both discovery and replication phases [22]. 126 
Quantitative global genetic ancestry estimates were also obtained for the populations included 127 
in the discovery phase. An unsupervised model was applied using ADMIXTURE [23], 128 
assuming the European (CEU), African (YRI) and Native American (NAM) as the parental 129 
populations for the Hispanics/Latinos and YRI and CEU for African Americans. For that, 130 
reference haplotypes from CEU and YRI populations from the HapMap Project Phase III [24] 131 
were used. Moreover, haplotypes from individuals genotyped with Axiom® LAT1 array 132 
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(Affymetrix Inc.) were considered as reference for NAM population, as described elsewhere 133 
[19, 25]. 134 
In all the studies, imputation was carried out by means of the Michigan Imputation 135 
Server (https://imputationserver.sph.umich.edu) using the second release of the Haplotype 136 
Reference Consortium (HRC) (r1.1 2016) as reference panel [26]. Haplotype reconstruction 137 
and imputation were performed with SHAPEIT v2.r790 [27] and Minimac3 [28], 138 
respectively. 139 
Association testing and meta-analysis in the discovery phase 140 
GWAS analyses were carried out separately for GALA II and SAGE. Logistic 141 
regressions were used to evaluate the association between genetic variants and ICS response 142 
by means of the binary Wald test implemented in EPACTS 3.2.6 [29]. The presence or 143 
absence of any asthma exacerbations during the last 12 or 6 months in patients treated with 144 
ICS was considered as a measure of ICS response, which was evaluated as a binary variable. 145 
Age, gender, and the first two PCs, obtained with EIGENSOFT 6.14 [22], were included as 146 
covariates in the regression models. The number of PCs included as covariates was chosen 147 
based on the comparison of different models that included up to 10 PCs, showing that results 148 
based on 2 PCs had the best fit with the expected values under the null hypothesis of no 149 
association. 150 
Single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF)≥1% and 151 
with imputation quality (Rsq)≥0.3 in GALA II and SAGE, and shared among both 152 
populations were meta-analyzed using METASOFT [30]. Fixed-effects or random-effects 153 
models were selected for each variant depending on absence or presence of heterogeneity, 154 
respectively, which was assessed by means of the Cochran Q-test. A threshold of p-155 
value≤5x10-6 was arbitrarily set to select variants suggestively associated with asthma 156 
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exacerbations, since this threshold is commonly adopted in GWAS studies [31-35]. Among 157 
those variants, independent associations were detected by means of logistic regression 158 
analyses conditioned on the most significant SNP of each locus using R 3.4.3 [36]. This 159 
analysis provided a list of independent variants that were followed up for replication.  160 
Association testing and meta-analysis in the replication phase 161 
Statistical analyses were performed following the same methodology as in the discovery 162 
phase, except for the definition of asthma exacerbations available in each study and the 163 
number of PCs included as covariates in the association analyses (Table S1). Evidence of 164 
replication was considered for those SNPs that showed a combined p-value≤0.05 in a meta-165 
analysis of all the European studies and consistent directions of effects in both discovery and 166 
validation populations. 167 
Association with ICS response measured as change in FEV1 168 
SNPs significantly associated with asthma exacerbations in both admixed and European 169 
populations, were evaluated for association with the change in the forced expiratory volume 170 
in 1 second (FEV1) after 6 weeks of treatment with ICS in 166 ICS users from the 171 
SLOVENIA study, the only cohort included in the analyses with this outcome measured. This 172 
variable was dichotomized to define responders and non-responders to ICS treatment using a 173 
cutoff of ≥8% improvement of FEV1, which has been established as a good predictor of 174 
asthma severity in children [37]. Logistic regression models were applied including age, 175 
gender, and the first two PCs as covariates.  176 
Functional evaluation of variants associated with ICS response 177 
Functional annotation and evidence of significant expression quantitative trait loci 178 
(eQTL) were searched with HaploReg v4.1[38] based on data provided by the Encyclopedia 179 
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of DNA Elements (ENCODE) project [39]. This was performed for the SNP associated with 180 
ICS response in admixed and European populations and those in high linkage disequilibrium 181 
(LD) (r2>0.9) according to African populations from the 1000 Genomes Project (1KGP) data 182 
incorporated by HaploReg v4.1. Gene expression was inspected using the Portal for the 183 
Genotype-Tissue Expression (GTEx) [40] and the Gene Expression Atlas [41]. Moreover, 184 
evidence of association with enhancers was searched using the multiple sources available 185 
from GeneHancer [42]. 186 
Validation of previous associations in admixed populations  187 
Since previous GWAS of ICS response have focused on European and Asian 188 
populations [8-15], we attempted to validate their results in admixed populations. A total of 189 
25 SNPs near or within 14 genes declared as associated with ICS response [8-14], were 190 
followed up for replication in GALA II and SAGE.  191 
Replication was attempted at the SNP level and also as genomic region, the latter 192 
considering variants located within 100 kilobases (kb) upstream or downstream from the gene 193 
where the variant was located or from the two closest genes in case the variant was intergenic. 194 
Evidence of replication was considered for SNPs nominally associated with ICS response 195 
(p≤0.05) that had the same direction of the effect as the published GWAS. For the replication 196 
at level of genomic region, a Bonferroni-like correction was applied to account for the 197 
number of independent variants tested within each genomic region, as estimated with 198 
empirical autocorrelations based on Markov Chain Monte Carlo (MCMC) simulations. For 199 
this, an autocorrelation matrix was obtained based on the -log10 p-value of each SNP analyzed 200 
using the effectiveSize function from the R package coda [43], as described elsewhere [44]. 201 
According to this, a Bonferroni-corrected significance threshold was estimated for each 202 
genomic region with α=0.05/number of independent variants. 203 
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RESULTS 204 
Characteristics of the study populations 205 
The characteristics of the 1,347 admixed asthmatic patients from GALA II and SAGE 206 
analyzed in the discovery phase and the 1,697 Europeans subjects included in the replication 207 
are shown in Table 1 and Table S1, respectively. In terms of estimates of global ancestry in 208 
the admixed populations, Hispanics/Latinos had 13.6% African ancestry, 51.5% European 209 
ancestry and 34.9% Native American ancestry. In contrast, African Americans had 79.4% 210 
African admixture and 20.6% European ancestry. Hispanics/Latinos reported a higher 211 
proportion of asthma exacerbations in the 12 months preceding study enrollment (66.4%) than 212 
African Americans (51.9%). Although asthma exacerbations were differentially defined in the 213 
validation populations, similar proportions were found across the discovery and replication 214 
studies, except for PACMAN and SLOVENIA, with values of 11.0% and 34.1%, respectively 215 
(Table S1). 216 
Discovery phase 217 
The meta-analysis of the GALA II and SAGE GWAS included 8.7 million SNPs that 218 
were shared among Hispanics/Latinos and African Americans and had MAF≥1% and 219 
Rsq≥0.3. The Q-Q plots of the association results for each individual study (Figure S1A and 220 
Figure S1B) and those obtained after combining both admixed populations did not reveal 221 
major genomic inflation due to population stratification (λGC = 1.04, Figure S1C). Although 222 
the genome-wide significant threshold (p-value≤5x10-8) was not reached by any of the 223 
variants, 27 SNPs with Rsq values ranging from 0.59-1.00 and located near or within 13 loci 224 
were suggestively associated with asthma exacerbations despite the use of ICS (p-value≤5x10-225 
6) in admixed children and young adults (Figure 1 and Table S2). 226 
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After performing pairwise regression models conditioned on the most significant variant 227 
for each locus with at least two suggestive associations, one independent variant was detected 228 
per locus, except for APOBEC3B-APOBEC3C and ANKRD30B, where two SNPs remained 229 
significant after conditioning on each gene’s most significant variant (Table S3). As a result, 230 
15 SNPs were identified as independently associated with ICS response in admixed 231 
populations (Table S3) and were followed up for replication.  232 
Replication phase 233 
Of the 15 SNPs selected for replication in Europeans, 11 SNPs had a MAF≥1% and 234 
Rsq≥0.3 (ranging from 0.36-1.00) in Europeans and were forwarded for replication (Table 2). 235 
Of those, rs5995653, located within the intergenic region of APOBEC3B and APOBEC3C 236 
(Figure 2), showed evidence of nominal replication after combining the European studies. To 237 
check that the association of this SNP in the admixed populations was not confounded by 238 
unaccounted components of ancestry, different regression models were tested including 239 
estimates of genetic ancestry, different number of PCs, or following the method described by 240 
Conomos et al. [45], which provided similar results (Table S4). The direction of effect for 241 
this SNP was the same in Europeans (OR for A allele: 0.76, 95% CI: 0.62-0.93, p = 7.52x10-242 
3) as in the admixed samples (OR for A allele = 0.66, 95% CI: 0.56-0.79, p = 4.80x10-6) 243 
(Table 2). A meta-analysis of this SNP across the two phases resulted in a suggestive 244 
genome-wide significant association (OR for A allele = 0.70, 95% CI: 0.61-0.81, p = 3.31x10-245 
7, Figure 3).  246 
Association of rs5995653 with ICS response measured as change in FEV1 247 
The SNP rs5995653 was significantly associated with a positive response to the ICS 248 
treatment in SLOVENIA, measured as an increase of FEV1 (OR for A allele = 2.16, 95% CI: 249 
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1.26-3.70, p = 4.91x10-3), which is concordant with the protective effect of this SNP with 250 
asthma exacerbations in both discovery and validation studies.  251 
In silico functional role of the novel association detected 252 
The experimental data provided by the ENCODE project shows that the SNP rs5995653 253 
is located within a histone H3 lysine 4 mono-methylation (H3K4me1) mark of an active gene 254 
enhancer and a DNAse hypersensitivity site in blood cells [39]. This is concordant with the 255 
GeneHancer evidence that APOBEC3B has been associated with enhancers that regulate 256 
multiple transcription factor binding sites, indicating its involvement in the regulation of gene 257 
expression in different cell types, including lung fibroblasts [42]. Moreover, this variant is 258 
also in high LD with several eQTL in blood cells associated with the expression of 259 
APOBEC3A (rs9607601: p=1.80x10-13 and rs5995654: p=9.10x10-14), APOBEC3G 260 
(rs9607601: p=0.003), and CBX6 (rs9607601: p=3.94x10-4 and rs5995654: p=4.00x10-4) [38-261 
39, 46]. In addition, previous functional studies have evidenced high levels of gene expression 262 
of both APOBEC3B and APOBEC3C in pulmonary cells (GTEx) [40-41]. 263 
Validation of previous associations of ICS response 264 
None of the 25 SNPs previously associated with ICS response was consistently 265 
associated with asthma exacerbations in admixed populations (Table S5). To assess whether 266 
the lack of replication of previous GWAS hits could be due to the association of alternative 267 
genetic variants among different populations, a replication analysis was also performed at 268 
genomic region level. A total of 36,261 variants located within 100 kb upstream and 269 
downstream from 14 loci previously associated with ICS response were evaluated. After 270 
applying a Bonferroni-like correction for the number of variants analyzed within each 271 
genomic region, suggestive associations were observed for nine SNPs near three genomic 272 
regions: ALLC (min p-value = 4.69x10-4 for the SNP rs113903375), L3MBTL4-ARHGAP28 273 
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(min p-value = 1.57x10-5 for the SNP rs62081416), and ELMO2-ZNF334 (min p-value = 274 
3.56x10-4 for the SNP rs2425845) (Table S6). However, applying a more restrictive 275 
correction for the total number of independent variants across all genomic regions (p 276 
≤1.71x10-5 for 2,916 independent variants tested), only the association of rs62081416, located 277 
within the intergenic region of L3MBTL4 and ARHGAP28, was significantly associated with 278 
ICS response in admixed individuals (OR for A allele = 2.44, 95% CI: 1.63-3.65, p = 1.57x10-279 
5). 280 
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DISCUSSION 281 
In this study, we carried out the first GWAS of ICS response in Hispanic/Latino and 282 
African American children and young adults with asthma. After combining the association 283 
results from these two populations, 15 independent suggestive association signals were 284 
associated with asthma exacerbations despite use of ICS, and one of them showed evidence of 285 
nominal replication in Europeans. This SNP was also significantly associated with an increase 286 
in FEV1 after 6 weeks of treatment with ICS in one of the European studies where this 287 
outcome was measured. These results revealed for the first time the association of 288 
APOBEC3B and APOBEC3C genes with ICS response in asthmatic children and young 289 
adults. Additionally, we validated the association of the L3MBTL4-ARHGAP28 genomic 290 
region in admixed populations, which was previously described in a GWAS of ICS response 291 
in subjects of European descent.  292 
The APOBEC3B and APOBEC3C genes encode two members of the apolipoprotein B 293 
mRNA-editing catalytic polypeptide 3 (APOBEC3) family. APOBEC3 proteins are involved 294 
in RNA editing through the deamination of cytidine to uracil [47]. Their main function is 295 
related to innate immunity and are considered important restriction factors against a broad 296 
range of viruses [48]. However, APOBEC3 proteins are also involved in cellular processes 297 
related to mutagenic activity [49], including the development of several types of cancer, while 298 
APOBEC3B specifically has been associated with an increased risk of lung cancer [50]. 299 
We found that the A allele of rs5995653, located 5.8 kb from the 3’UTR of 300 
APOBEC3C, showed a protective effect against asthma exacerbations and was associated 301 
with improvement on FEV1 in patients treated with ICS. While no asthma-related functions 302 
have been attributed to any of the APOBEC3 flanking genes, evidence of high levels of RNA 303 
expression has been found in pulmonary fibroblasts for both genes [40-41]. Furthermore, the 304 
functional evidence found for rs5995653 suggests that this SNP plays a key role in regulating 305 
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the expression of genes involved in several cellular processes in the lung. Interestingly, 306 
respiratory viral infections are important risk factors for exacerbations in asthmatic children 307 
[51]. This fact is concordant with the consistent function of APOBEC3B and APOBEC3C as 308 
restrictors of viral infections, suggesting that the expression of these genes in pulmonary 309 
tissues could be involved in fighting against viral-induced asthma exacerbations in patients 310 
treated with ICS.  311 
Our study has several strengths. First, this is the largest meta-GWAS of ICS response 312 
with a discovery phase specifically focused on Hispanic/Latino and African American asthma 313 
patients, the minority ethnic groups most affected by asthma in the United States [4]. 314 
Admixed populations with African and Native American have been underrepresented in the 315 
asthma pharmacogenomic studies of ICS response [4]. Secondly, we identified a novel 316 
association shared among admixed and European populations, which could be also influential 317 
in other populations. Third, we validated the association of three genomic regions previously 318 
described in GWAS of ICS response in European and Asian populations [11, 13] and one of 319 
them was associated with an improvement in FEV1 after treatment with ICS in adults [11]. 320 
This evidence reinforces the validity of asthma exacerbations as a good measure of response 321 
to the asthma treatment with ICS. Finally, the fact that the intergenic region of L3MBTL4 and 322 
ARHGAP28 has been previously identified in adults could suggest the existence of common 323 
genetic markers of ICS response among adulthood and childhood asthma [13]. 324 
We recognize some limitations of our study. First, the most significant variant 325 
associated with ICS response in admixed and European populations did not reach genome-326 
wide significance. This result was replicated in independent samples at nominal level, 327 
although it would not still be significant after a multiple comparison correction. Second, this 328 
study did not include a considerable larger sample size compared to the largest GWAS of ICS 329 
response published to date [17]. Third, even though the HRC reference panel is the largest 330 
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catalogue of variants from the whole genome available to date [26], admixed populations with 331 
African and Native American ancestries are not well represented. Fourth, asthma 332 
exacerbations were differentially defined in the European populations included in the 333 
replication phase. Nevertheless, this outcome was homogeneously defined in the studies 334 
included in the discovery phase, suggesting that the identified locus is robustly associated 335 
with asthma exacerbation across a range of definitions. Fifth, ICS response was evaluated as 336 
the presence or absence of asthma exacerbations in asthmatic patients with a self-reported use 337 
of ICS, which might not correspond to compliance or changes with the asthma control 338 
therapy. For this reason, the association signal detected was followed up for replication using 339 
a quantitative measurement of ICS response, which was only available in one of the European 340 
populations. Additional studies should seek to validate the association signal when using 341 
change in FEV1 after the treatment with ICS as the response variable. Finally, functional 342 
evidence relating the intergenic region of APOBEC3B and APOBEC3C with ICS response in 343 
asthma patients was not directly assessed in this current study, since only experimental data 344 
available in public databases was queried. Therefore, in vitro experiments in relevant tissues 345 
and cell types for ICS response are needed to evaluate the functional roles of these loci in 346 
order to confirm their implication in this trait.  347 
In summary, our meta-GWAS in admixed children and young adults identified a novel 348 
association of genetic variants from the intergenic region of APOBEC3B and APOBEC3C as 349 
with ICS response in subjects with asthma. We also validated the association of one genomic 350 
region previously associated with ICS response. Our study demonstrates the advantages of 351 
including admixed populations in asthma pharmacogenomic studies of ICS response. 352 
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FIGURE LEGENDS 531 
Figure 1. Manhattan plot of association results of ICS response in the discovery phase. 532 
Association results are represented as -log10 p-value on the y-axis along the chromosomes (x-533 
axis). The suggestive significance threshold for replication is indicated by the black line 534 
(p≤5x10-6). 535 
Figure 2. Regional plot of association results in the discovery phase for the APOBEC3B-536 
APOBEC3C intergenic region, which represents a novel association with ICS response. 537 
Statistical significance of association results (-log10 p-value) (y-axis) is represented by 538 
chromosome position (x-axis) for each SNP as a dot. A diamond represents the independent 539 
association signal with evidence of replication in Europeans (rs5995653) and the remaining 540 
SNPs are color-coded based on their LD with this SNP, indicated by pairwise r2 values for 541 
American populations from the 1KGP. 542 
Figure 3. Forest plot of association effect of rs5995653 across studies. Odds ratio (OR) for 543 
the effect allele (A) is shown for each study and after combining them by black boxes and a 544 
blue diamond. Black dash lines indicate the corresponding 95% Confidence Intervals (95% 545 
CI) for each individual study.  546 
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TABLES 
Table 1. Clinical and demographic characteristics of the admixed populations analyzed in the 
discovery phase. 
   
GALA II                                                   
(n = 854)  
SAGE                                                          
(n = 493) 
Gender (% male)  57.3  54.2 
Mean age ± SD (years)  12.1 ± 3.2  13.5 ± 3.4 
Ethnicity  Hispanic/Latino  African American 
Mean genetic ancestry (%)     
      African  13.6  79.4 
      European  51.5  20.6 
      Native-American  34.9  NA 
Asthma exacerbations in the last 12 
months (%)  66.4  51.9 
      Emergency asthma care (%)  56.6  43.2 
      OCS use (%)  40.2  29.4 
      Hospitalizations (%)  12.6  5.7 
SD: standard deviation; OCS: oral corticosteroids; NA: not available. 
547 
548 
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Table 2. Association results for the suggestive SNPs followed up for replication in European populations. 
      Admixed populations (n=1,347)  
European populations 
 (n=1,697) 
SNP  Chr.a Positionb Nearest gene(s) A1/A2  Freq.
c  OR (95% CI)
d p-value  Freq.
c  OR (95% CI)
d p-value 
rs11121611 1 6367219 ACOT7 G/T  0.201  0.55 (0.43-0.70) 1.65 x 10
-6  0.062  0.97 (0.61-1.56) 0.247 
e 
rs35514893 6 15909525 DTNBP1-MYLIP T/C  0.020  0.36 (0.23-0.55) 2.86 x 10
-6  0.082  0.73 (0.22-2.46) 0.613 
rs4897302 6 123886231 TRDN T/C  0.505  1.58 (1.31-1.91) 1.75 x 10
-6  0.221  0.96 (0.81-1.13) 0.637 
rs61585310 7 104006510 LHFPL3 G/T  0.796  0.61 (0.49-0.75) 2.85 x 10
-6  0.763  0.91 (0.74-1.11) 0.352 
rs7851998 9 126828514 LHX2-NEK6 A/G  0.191  0.56 (0.44-0.72) 3.97 x 10
-6  0.046  0.83 (0.65-1.06) 0.132 
rs2125362 11 86167136 ME3 A/G  0.684  1.31 (0.68-2.56) 3.53 x 10
-6 e  0.750  0.97 (0.82-1.16) 0.764 
rs450789 13 33578233 KL G/A  0.334  0.64 (0.53-0.77) 3.33 x 10
-6  0.271  0.97 (0.83-1.15) 0.756 
rs12959468 18 15182381 ANKRD30B-ROCK1 A/G  0.039  0.39 (0.26-0.58) 2.99 x 10
-6  0.077  1.39 (0.74-2.62) 0.309 
rs2278992 19 18095769 KCNN1 C/T  0.176  0.59 (0.47-0.74) 3.76 x 10
-6  0.151  1.00 (0.81-1.24) 0.991 
rs6001366 22 39399941 APOBEC3B-APOBEC3C T/C  0.079  0.47 (0.35-0.65) 2.53 x 10
-6  0.064  1.00 (0.72-1.38) 0.995 
rs5995653 22 39404249 APOBEC3B-APOBEC3C A/G   0.285  0.66 (0.56-0.79) 4.80 x 10
-6  0.508  0.76 (0.62-0.93) 7.52 x10
-3 
aChromosome; bPositions based on GRCh37/hg19 build; cFrequency of the effect allele; dOdds ratio for the effect alleles (additive model); eRandom-effect model was 
applied since heterogeneity was found between admixed/European populations. A1: Effect allele; A2: Non-effect allele; CI: Confidence Interval.  
  
 
 
